System biosciences inc

    • investor.assemblybio.com

      ASSEMBLY BIOSCIENCES, INC. (Last)(First)(Middle) C/O ASSEMBLY BIOSCIENCES, INC. 331 OYSTER POINT BLVD., FOURTH FLOOR ... the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached ...

    • [DOC File]ResearchGate

      https://info.5y1.org/system-biosciences-inc_1_3f6c64.html

      IRF9 antibody was obtained from LSBio (Life Span BioSciences, Inc). (-actin, STAT2 (sc-476), phospho-STAT2 (Tyr690) were purchased from Santa Cruz Biotechnology; anti-rabbit or anti-mouse IRDye ...

    • Castle Biosciences, Inc.

      Castle Biosciences, Inc. (the ‘‘Company’’) was incorporated in the state of Delaware on September 12, 2007. The Company is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.

    • Pacific Biosciences of California

      PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) NOTE 1. OVERVIEW. Pacific Biosciences of California, Inc., (“Pacific Biosciences”, the “Company”, “we”, “us”) has commercialized the PacBio RS II Sequencing System to help scientists solve genetically complex problems.

    • Overview - Precision BioSciences

      Precision BioSciences, Inc., a Delaware corporation (the “ Company ”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “ Agent ”), shares of the Company’s common stock, par value $0.000005 per share (the “ Common Shares

    • investor.pacificbiosciences.com

      Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware. 001-34899. 16-1590339 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification No.) 1380 Willow Road. Menlo Park, California 94025 (Address of principal executive offices, including zip code ...

    • Pulse Biosciences Inc.

      On July 31, 2018, Pulse Biosciences, Inc. announced its financial results for the three- and six-month periods ended June 30, 2018. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

    • investor.precisionbiosciences.com

      Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

    • ir.codiakbio.com

      execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Codiak BioSciences, Inc. (the "Company"), from time to time the following U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID, including any attached documents (such as Update Passphrase Authentication), to effect the ...

    • [DOC File]Outline of NR paper – Rutgers data

      https://info.5y1.org/system-biosciences-inc_1_258647.html

      Probes were labeled with (32P-dATP using the Prime-A-Gene Labeling System (Promega Biosciences Inc., Madison, WI). Hybridization was performed using the PerfectHyb system (Ambion Inc., Austin, TX). The blots were washed twice with 0.2 x SSC followed by 30 min incubation at 42ºC before being exposed to Kodak BioMax MR/MS films.

    • [DOC File]NIH-CAP Company Descriptions 2008-09

      https://info.5y1.org/system-biosciences-inc_1_7e59e6.html

      Vivo Biosciences Inc. (VBI) is a small biotechnology company dedicated to developing novel 3-D or in vivo-like bioassay platforms (HuBiogel™) for predicting drug efficacy/toxicity in humans and thus advancing drug discovery and therapeutics.

    • [DOCX File]Home | Cancer Discovery

      https://info.5y1.org/system-biosciences-inc_1_c2f56a.html

      The chemiluminescent images were acquired with a C-DiGit Imaging System (LI-COR Biosciences). The relative density of the chemiluminescent bands were quantified via Image Studio Digits from LICOR. The half inhibitory concentration (IC 50 ) value is calculated using non-linear regression analysis through GraphPad Prism software (GraphPad, Inc ...

    • Pulse Biosciences Inc.

      HAYWARD, Calif. - (BUSINESS WIRE) – April 30, 2019 – Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and financial results for the quarter ended March 31, 2019.

    • ir.castlebiosciences.com

      CASTLE BIOSCIENCES, INC. By:/s/ Frank Stokes. Frank Stokes. Chief Financial Officer. Date: August 10, 2020. Exhibit 99.1. Castle Biosciences Announces Second Quarter 2020 Results. Q2 2020 revenues of $12.7 million, compared to $10.7 million in Q2 2019. DecisionDx-Melanoma test report volume decreased 19% compared to Q2 2019. Gross margin of 83%

    • [DOC File]Aastrom Biosciences, Inc

      https://info.5y1.org/system-biosciences-inc_1_7f4502.html

      The culture medium (Base Medium, Aastrom Biosciences, Inc., Ann Arbor, MI, USA) consists of Iscove’s Modified Dulbecco’s Media (IMDM), 10% fetal bovine serum, 10% horse serum, 5 μM hydrocortisone, gentamycin sulfate, and vancomycin.

Nearby & related entries:

To fulfill the demand for quickly locating and searching documents.

It is intelligent file search solution for home and business.

Literature Lottery

Advertisement
Hot searches

©2024 5y1.org, Inc. All rights reserved.